Core Viewpoint - JingTai Holdings (02228) reported a significant turnaround in its interim results for the six months ending June 30, 2025, with a revenue of 517 million RMB, marking a year-on-year increase of 403.83% and a net profit attributable to shareholders of 82.795 million RMB, compared to a loss of 1.237 billion RMB in the same period last year [1] Financial Performance - Revenue for the drug discovery solutions business surged from 60.9 million RMB for the six months ending June 30, 2024, to 435 million RMB for the same period in 2025, reflecting a growth of 615.2% [1] - The company achieved a monthly average cash burn reduction of 20.0%, bringing it down to 49.7 million RMB [1] - Adjusted net profit for the first half of the year reached 142 million RMB, marking the first time the company achieved half-year profitability [1] Strategic Developments - The revenue growth was primarily driven by a significant collaboration with DoveTree Medicines LLC and its affiliates, with the company reaching the first milestone of this partnership and receiving an initial payment of 51 million USD [1] - The company ended the reporting period with a cash balance of 5.308 billion RMB, indicating a strong financial position [1]

Core Viewpoint - Crystal Tech Holdings (02228) reported a significant turnaround in its financial performance for the six months ending June 30, 2025, with a revenue increase of 403.83% year-on-year, reaching 517 million RMB, and a shift from a loss of 1.237 billion RMB to a profit of 82.795 million RMB for shareholders [1] Financial Performance - Revenue for the drug discovery solutions business surged by 615.2%, from 60.9 million RMB for the six months ending June 30, 2024, to 435 million RMB for the same period in 2025, primarily driven by a major collaboration with DoveTree Medicines LLC [1] - The company achieved a milestone in its collaboration with DoveTree, receiving an initial payment of 51 million USD [1] - The antibody business also demonstrated strong revenue growth during the reporting period [1] Cash Position and Profitability - As of the end of the reporting period, the company had a cash balance of 5.308 billion RMB, indicating a solid financial position [1] - Monthly average cash consumption decreased by 20.0% to 49.7 million RMB during the first half of the year [1] - The adjusted net profit for the first half of the year was 142 million RMB, marking the first time the company achieved half-year profitability, signifying a new growth phase for the company [1]